Bridging the divide: preclinical research discrepancies between triple-negative breast cancer cell lines and patient tumors.

ABSTRACT: Triple-negative breast cancer (TNBC) is the most refractory subtype of breast cancer and disproportionately accounts for the majority of breast cancer related deaths. Effective treatment of this disease remains an unmet medical need. Over the past several decades, TNBC cell lines have been used as the foundation for drug development and disease modeling. However, ever-mounting research demonstrates striking differences between cell lines and clinical TNBC tumors, disconnecting bench research and actual clinical responses. In this review, we discuss the limitations of cell lines and the importance of using patients' tumors for translational research, and highlight the usage of patient-derived xenograft (PDXs) models that have emerged as a clinically relevant platform for preclinical studies

SUBMITTER: Sulaiman A 

PROVIDER: S-EPMC5762590 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature